Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Tectonic Therapeutic, Inc. (NASDAQ:TECX) has been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $81.50.

A number of brokerages have commented on TECX. Truist Financial decreased their price target on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Lifesci Capital upgraded shares of Tectonic Therapeutic to a “strong-buy” rating in a report on Thursday, February 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Thursday, January 22nd.

Insider Buying and Selling

In related news, CFO Daniel Lochner purchased 6,000 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was acquired at an average cost of $21.61 per share, with a total value of $129,660.00. Following the transaction, the chief financial officer owned 32,044 shares of the company’s stock, valued at $692,470.84. This represents a 23.04% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Mcnamara sold 6,262 shares of Tectonic Therapeutic stock in a transaction on Friday, March 6th. The stock was sold at an average price of $30.17, for a total transaction of $188,924.54. Following the transaction, the insider directly owned 55,285 shares in the company, valued at $1,667,948.45. This represents a 10.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 19,561 shares of company stock worth $566,551. 9.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of institutional investors have recently added to or reduced their stakes in TECX. Aberdeen Group plc grew its stake in Tectonic Therapeutic by 220.6% in the 4th quarter. Aberdeen Group plc now owns 1,141,824 shares of the company’s stock valued at $23,818,000 after purchasing an additional 785,648 shares during the period. Braidwell LP grew its position in Tectonic Therapeutic by 25.9% during the fourth quarter. Braidwell LP now owns 927,524 shares of the company’s stock valued at $19,348,000 after buying an additional 190,657 shares during the period. Baker BROS. Advisors LP raised its position in Tectonic Therapeutic by 803.4% in the fourth quarter. Baker BROS. Advisors LP now owns 903,400 shares of the company’s stock worth $18,845,000 after acquiring an additional 803,400 shares during the period. 5AM Venture Management LLC boosted its stake in Tectonic Therapeutic by 18.6% in the fourth quarter. 5AM Venture Management LLC now owns 606,660 shares of the company’s stock valued at $12,655,000 after acquiring an additional 95,000 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new position in shares of Tectonic Therapeutic during the 4th quarter valued at approximately $11,986,000. 62.63% of the stock is owned by institutional investors.

Tectonic Therapeutic Price Performance

Shares of TECX opened at $34.00 on Tuesday. The stock has a 50-day moving average of $22.05 and a 200-day moving average of $19.80. The company has a market cap of $638.52 million, a PE ratio of -8.40 and a beta of 3.75. Tectonic Therapeutic has a one year low of $13.70 and a one year high of $36.03.

Tectonic Therapeutic (NASDAQ:TECX) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.08. Analysts expect that Tectonic Therapeutic will post -8.31 EPS for the current fiscal year.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.